S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:HALOHalozyme Therapeutics Stock Price, Forecast & News

$28.20
-0.44 (-1.54 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.53
Now: $28.20
$29.29
50-Day Range
$24.44
MA: $27.31
$29.27
52-Week Range
$12.71
Now: $28.20
$29.64
Volume1.23 million shs
Average Volume1.55 million shs
Market Capitalization$3.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.
Read More
Halozyme Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.99 million
Book Value$0.63 per share

Profitability

Net Income$-72,240,000.00

Miscellaneous

Employees281
Market Cap$3.83 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$28.20
-0.44 (-1.54 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

How has Halozyme Therapeutics' stock been impacted by COVID-19?

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HALO shares have increased by 54.8% and is now trading at $28.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Halozyme Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Halozyme Therapeutics
.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its earnings results on Monday, August, 10th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by $0.06. The biopharmaceutical company earned $55.22 million during the quarter, compared to analyst estimates of $65.81 million. Halozyme Therapeutics had a negative return on equity of 48.92% and a negative net margin of 48.75%. Halozyme Therapeutics's quarterly revenue was up 41.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.10) earnings per share.
View Halozyme Therapeutics' earnings history
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY20 earnings guidance on Monday, August, 10th. The company provided earnings per share (EPS) guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.77. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $235.21 million.

What price target have analysts set for HALO?

11 equities research analysts have issued 1-year price objectives for Halozyme Therapeutics' shares. Their forecasts range from $20.00 to $43.00. On average, they anticipate Halozyme Therapeutics' share price to reach $31.36 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics
.

Has Halozyme Therapeutics been receiving favorable news coverage?

News stories about HALO stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Halozyme Therapeutics
.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Gilead Sciences (GILD), Micron Technology (MU), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and Aegean Marine Petroleum Network (ANW).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
  • Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
  • Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
  • Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
  • Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (4.84%), Third Security LLC (2.59%), New York State Common Retirement Fund (1.22%), Victory Capital Management Inc. (1.13%), First Eagle Investment Management LLC (1.12%) and Goldman Sachs Group Inc. (1.09%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros, Kenneth J Kelley, Michael J Labarre and Randal J Kirk.
View institutional ownership trends for Halozyme Therapeutics
.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, Prudential Financial Inc., MERIAN GLOBAL INVESTORS UK Ltd, First Eagle Investment Management LLC, Fisher Asset Management LLC, RMB Capital Management LLC, Granite Investment Partners LLC, and Trexquant Investment LP.
View insider buying and selling activity for Halozyme Therapeutics
.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Lateef Investment Management L.P., AMI Asset Management Corp, Goldman Sachs Group Inc., Redwood Investments LLC, Scout Investments Inc., AJO LP, and Foundry Partners LLC.
View insider buying and selling activity for Halozyme Therapeutics
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $28.20.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $3.83 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.